Laurence Reid Biography and Net Worth

Director of Metagenomi

Dr. Reid currently serves as chairperson of the board of directors of Broken String Biosciences Ltd. and on the boards of directors of KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) and several other private biotechnology companies. Previously, Dr. Reid was president and CEO of Decibel Therapeutics, Inc., until its acquisition by Regeneron Pharmaceuticals, Inc. in 2023, and CEO of Warp Drive Bio, LLC until its merger with Revolution Medicines, Inc. in 2018. He has also served as an entrepreneur in residence at Third Rock Ventures LLC.

Prior to that, Dr. Reid served as Chief Business Officer of Alnylam Pharmaceuticals, Inc., and as General Manager of Millennium Europe at Millennium Pharmaceuticals, Inc., which is now part of Takeda Pharmaceutical Company Limited. He received a BA in Natural Sciences from Cambridge University and a PhD in biochemistry from King’s College, University of London.

What is Laurence Reid's net worth?: The estimated net worth of Laurence Reid is at least $23.10 thousand as of September 9th, 2026. Dr. Reid owns 20,000 shares of Metagenomi stock worth more than $23,100 as of September 25th. This net worth estimate does not reflect any other assets that Dr. Reid may own. Learn More about Laurence Reid's net worth.
How do I contact Laurence Reid?: The corporate mailing address for Dr. Reid and other Metagenomi executives is 5959 Horton Street, 7th Floor, Emeryville, CA, 94608. Metagenomi can also be reached via phone at 510-871-4880 and via email at [email protected]. Learn More on Laurence Reid's contact information.
Has Laurence Reid been buying or selling shares of Metagenomi?: During the last ninety days, Laurence Reid has bought $23,400.00 of Metagenomi stock. Most recently, on Wednesday, September 9th, Laurence Reid bought 20,000 shares of Metagenomi stock. The stock was acquired at an average cost of $1.17 per share, with a total value of $23,400.00. Following the completion of the transaction, the director now directly owns 20,000 shares of the company's stock, valued at $23,400. Learn More on Laurence Reid's trading history.
Who are Metagenomi's active insiders?: Metagenomi's insider roster includes Laurence Reid (Director), and Brian Thomas (Founder & Former CEO). Learn More on Metagenomi's active insiders.
Are insiders buying or selling shares of Metagenomi?: During the last year, Metagenomi insiders bought shares 1 times. They purchased a total of 20,000 shares worth more than $23,400.00. During the last year, insiders at the sold shares 4 times. They sold a total of 9,871 shares worth more than $15,847.42. The most recent insider tranaction occured on September, 9th when Director Laurence Reid bought 20,000 shares worth more than $23,400.00. Insiders at Metagenomi own 12.5% of the company. Learn More about insider trades at Metagenomi.
Information on this page was last updated on 9/9/2026.

Laurence Reid Insider Trading History at Metagenomi

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
9/9/2026	Buy	20,000	$1.17	$23,400.00	20,000

Laurence Reid Buying and Selling Activity at Metagenomi

Metagenomi Company Overview

Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.

Today's Range

Now: $1.16

$1.14

$1.17

50 Day Range

MA: $1.19

$1.10

$1.24

2 Week Range

Now: $1.16

$1.07

$3.95

Volume

28,331 shs

Average Volume

197,424 shs

Market Capitalization

$43.64 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.67